Navigation Links
AACR news: Studies show increasing evidence that androgen drives breast cancer
Date:4/10/2013

Estrogen and progesterone receptors, and the gene HER2 these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.

"This is a continuing line of work with all evidence pointing toward the addition of the androgen receptor as potential target and useful marker in all of the major subtypes of breast cancer," says Jennifer Richer, PhD, investigator at the University of Colorado Cancer Center and co-director of the CU Cancer Center Tissue Processing and Procurement Core.

The finding of androgen receptors (AR) as a potential target in breast cancer is especially important in light of its prevalence in breast cancers that don't express other hormone receptor targets or have developed resistance to treatments that target estrogen dependence. Overall, approximately 77 percent of breast cancers are positive for AR, including 88 percent of cancers that are estrogen receptor positive, 59 percent of those that are HER2 positive, and 20-32 percent of triple negative breast cancers.

The study presented this week explores the ability of estrogen-positive (ER+) breast cancers to develop resistance to anti-estrogen drugs by potentially developing an alternative addiction to AR and hypothesizes that anti-androgen therapy, such as the drug enzalutamide (formerly MDV3100) as successful counters to breast cancers' evolution. First, Richer and colleagues used breast cancer tumor registries to discover that cancers with higher ratios of AR to ER protein had shorter time to relapse after anti-estrogen therapies. Cut off from their estrogen addition, these cancers may have turned to growth and survival via androgens instead.

The group then returned to the lab to explore the effects of anti-androgen therapies in cell lines and preclinical models.

"Remarkably, the anti-androgen drug enzalutamide had effects comparable to the anti-estrogen drug tamoxifen in breast cancer cells that expressed both ER and AR," Richer says. HER2 cell lines that were also AR+ showed promising responses as well.

"We are excited to move toward clinical trials of anti-androgen therapies in breast cancer," Richer says. "And this study shows that patients with a high AR/ER ratio who relapse while on estrogen targeting therapies might be good candidates for this kind of therapy."


'/>"/>

Contact: Garth Sundem
garth.sundem@ucdenver.edu
805-559-2023
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Good news: Fewer maternal and child deaths
2. REACH news: European ombudsman takes up PETA complaint
3. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
4. AACR news: Six2 homeoprotein allows breast cancer cells to detach and metastasize
5. AACR news: Little molecule makes big difference in bladder cancer metastasis
6. AACR news: New target plus new drug equals death of melanoma cells
7. AACR news: K9 osteosarcoma samples identify drivers of metastasis in pediatric bone cancer
8. AACR news: Misregulated genes common to tobacco-related cancers offer potential new prognostic tool
9. Studies reveal structure of EV71, a virus causing childhood illnesses
10. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
11. Autism Speaks awards $1.1 million to fund high priority studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory ... experience and security for consumer electronics, and ... financial and retail industry, today announced a global ... convenient way to authenticate users of mobile banking ... TrulySecure™ software which requires no specialized ...
(Date:11/15/2016)... Research and Markets has announced the addition of the ... their offering. ... The global bioinformatics market ... 6.21 Billion in 2016, growing at a CAGR of 21.1% during ... is driven by the growing demand for nucleic acid and protein ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... CARDIFF, UK (PRWEB) , ... December 08, 2016 ... ... high precision light to control cells — optogenetics — is key to exciting ... state of the art, spatially patterned light projected via free-space optics stimulates small, ...
(Date:12/8/2016)... , December 8, 2016 ... expanded its customisable SureSeq™ NGS panel range with the launch ... fast and cost-effective study of variants in familial hypercholesterolemia (FH). ... variation (CNV) detection on a single small panel and allows ... content. This includes all exons for LDLR , ...
(Date:12/8/2016)... Frederick, Maryland (PRWEB) , ... ... ... Inc announces the commercial launch of flexible packaging for their exceptionally ... (“SU”) disposable bag system extends RoosterBio’s portfolio of bioprocess media products engineered ...
(Date:12/8/2016)...  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... and commercializing products to treat rare diseases where ... the long-term follow-up data from its Phase 2 ... Defense Regulator (IDR), in the treatment of oral ... undergoing chemoradiation therapy (CRT).  The additional 12-month safety ...
Breaking Biology Technology: